Superworth

Iradimed revenue IRMD

Sales by quarter and over the last twelve months, from 2013.

Last 12 months, to Sep 30, 2026
$89.3M
Latest quarter, Q3 FY26
$24.2M
+14% on a year earlier
Fiscal year 2025
$83.8M
+14% on the year before

Iradimed's revenue was $89.3M over the twelve months to Sep 30, 2026, up 11% on a year earlier.

In its latest quarter, Q3 FY26, it was $24.2M, up 14% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 21% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$83.8M+14%
FY2024$73.2M+12%
FY2023$65.6M+23%
FY2022$53.3M+27%
FY2021$41.8M+32%
FY2020$31.7M−18%
FY2019$38.5M+27%
FY2018$30.4M+32%
FY2017$23.1M−29%
FY2016$32.5M+3%
FY2015$31.6M+102%
FY2014$15.7M+38%
FY2013$11.3Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY26$24.2M+14%$89.3M
Q2 FY26$20.5M+0%$86.3M
Q1 FY26$22M+13%$86.3M
Q4 FY25$22.7M+17%$83.8M
Q3 FY25$21.2M+16%$80.5M
Q2 FY25$20.4M+14%$77.6M
Q1 FY25$19.5M+11%$75.2M
Q4 FY24$19.4M+11%$73.2M
Q3 FY24$18.3M+11%$71.3M
Q2 FY24$17.9M+11%$69.5M
Q1 FY24$17.6M+14%$67.7M
Q4 FY23$17.5M+17%$65.6M

Against its peers

Companies in Medical - Instruments & Supplies nearest Iradimed's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
IRMDIradimed$89.3M+11% a year
IARTIntegra Lifesciences$1.7B+1% a year
BVSBioventus$581.8M+4% a year
STAAStaar Surgical$339.6M+51% a year
CDRECadre$685.6M+20% a year
EYENational Vision$2B+8% a year
MOVMovado$689.9M+5% a year
LMATLemaitre Vascular$262.4M+12% a year
INSPInspire Medical Systems$898.7M−0% a year
TCMDTactile Systems Technology$350.3M+17% a year
UFPTUFP Technologies$631.6M+7% a year
Peer median$658.6M

Where Iradimed ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Iradimed

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.